EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([¹⁷⁷Lu]Lu-PSMA)

Excerpt

A paper regarding consensus statements on the role of prostate-specific membrane antigen (PSMA) PET/CT (e.g. [ ⁶⁸Ga]Ga-PSMA-11, [ ¹⁸F]PSMA-1007, [ ¹⁸F]DCFPyL, herein and further referred to as “PSMA PET/CT”) in patients with prostate cancer and in respect to radioligand therapy ([ ¹⁷⁷Lu]Lu-PSMA) has recently been published in Eur Urol Oncol [ 1], resulting from a collaboration between European Association of Nuclear Medicine (EANM) and European Association of Urology (EAU). It is well known that PSMA PET/CT is increasingly used for men with prostate cancer (PCa) in various clinical settings, and now incorporated in several international guidelines [ 2]; furthermore, procedural guidelines for performing PSMA PET/CT have been published [ 3]. …